Advaxis, Incorporated


Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.

Thursday, June 14, 2012

Advaxis ADXS-PSA Construct Causes Significant Tumor Regression in Preclinical Prostate Cancer Study

 Advaxis, Inc.,a leader in developing the next generation of immunotherapies for cancer and
infectious diseases, announced the publication of preclinical research with
ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy
targeting the PSA antigen associated with prostate cancer.

This research was conducted in collaboration with Dr. Chandan Guha and his
laboratory at Montefiore Medical Center, Bronx, NY. The paper titled
"Combined immunotherapy with Listeria
monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic
response in a murine model of prostate cancer" by
Hannan R, Zhang H, Wallecha A, Singh R, Liu L, Cohen P, Alfieri A, Rothman J,
and Guha C., has been e-published ahead of print in the journal Cancer
Immunology Immunotherapy.

The objective of the study was to determine if the combination of ADXS-PSA
immunotherapy and radiation therapy could improve upon the efficacy of either
immunotherapy alone or radiation therapy alone in the treatment of mice bearing
PSA-expressing TPSA23 tumors, a preclinical model of prostate cancer.

The study showed:

-- The combination of ADXS-PSA immunotherapy and radiation therapy resulted in
complete regression of established tumors in 60% of mice compared to less-than
or equal to 10% complete regression in either of the treatments alone.

-- In mice that completely regressed after combination therapy, tumors did not
develop upon re-challenge with tumor cells, suggesting the induction of systemic
and protective immune memory.

-- In addition, combination therapy resulted in increased induction of
PSA-specific T cells in the periphery and an increased infiltration of these
cells in the tumor microenvironment.

"ADXS-PSA continues to demonstrate activity in models
of prostate cancer, confirming our decision to move this construct into clinical
development. The potential synergy of ADXS-PSA and radiotherapy observed in this
study suggests that ADXS-PSA might be combined with other therapies that show
efficacy in this type of tumor," commented Dr. John
Rothman, EVP of Science and Operations at Advaxis.

The abstract is available online. 
 
http://ir.issuerdirect.com/adxs/read_press_release/2600
Posted by at